KeyBanc analyst Brett Fishbin lowered the firm’s price target on ICU Medical (ICUI) to $191 from $209 and keeps an Overweight rating on the shares. The firm believes underlying MedTech trends remain mostly positive heading into Q1 earnings season, but is lowering several price targets to reflect macro concerns around the potential impact of tariffs as well as an increased risk of recession.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI:
- ICU Medical announces FDA 510(k) clearance for Plum Solo, Plum Duo pumps
- ICU Medical added to Analyst Current Favorites list at Raymond James
- ICU Medical upgraded to Strong Buy from Outperform at Raymond James
- ICU Medical’s Earnings Call: Growth Amid Challenges
- ICU Medical Reports Revenue Growth Amid Net Loss